Significant progress in defining the biology of aging, particularly in animal models, supports the geroscience hypothesis, which posits that by therapeutically targeting biological aging, the onset of multiple age-related diseases can be delayed 'en suite'. Geroscience investigators are preparing to test this hypothesis in humans for the first time. In this review, we describe development of large-scale clinical trials designed to determine whether multiple age-related health conditions can be simultaneously alleviated with interventions targeting the underlying biology of aging. We describe the rationale and collaborative, consensus building approach used to design the first aging outcome trial called Targeting Aging with Metformin. Through this case study, we outline features that could be more broadly extended to other geroscience-guided clinical trials, including a process for selecting biochemical and molecular markers of biologic age and we provide a perspective on the potential impact of clinical trials targeting aging.
|Original language||English (US)|
|Number of pages||4|
|Journal||Cardiovascular Endocrinology and Metabolism|
|State||Published - Dec 1 2018|
Bibliographical noteFunding Information:
American Federation for Aging Research (AFAR); the Glenn Center for the Biology of Human Aging (Paul Glenn Foundation for Medical Research); National Institutes of Health: K01 AG059837-01 (J.N.J.), P30 AG021332 (S.K.B., J.N.J.); AG048023, AG052608, GM124922 (G.A.K.); P30 AG038072 (N.B.), P01 AG043376 (L.J.N., P.D.R.), U19 AG056278 (L.J.N., P.D.R., N.B.).
- clinical trials